Huabo Biomedical Technology (Shanghai)

Huabo Biopharm, a subsidiary of Huadong Medicine, is a clinical-stage biotechnology company based in Shanghai focused on the discovery and development of innovative biologics. The company specializes in monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) targeting oncology, immunology, and ophthalmology. Its pipeline includes several high-potential candidates such as HB0017, an anti-IL-17A antibody in Phase 3 trials, and HB0025, a PD-L1/VEGF bispecific antibody. Huabo leverages its proprietary technology platforms to advance therapies from early discovery through clinical development. As the core biologics R&D engine for its parent company, it plays a critical role in Huadong Medicine's transition toward an innovation-driven pharmaceutical leader.